Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.
- Dr Michael Thurn resigns as CEO, remains non-executive director until July 2026
- Interim Executive Chair Sergio Duchini appointed to maintain leadership continuity
- Global CEO search underway with Coulter Partners engaged
- Dr Thurn credited with advancing lead drug candidate NUZ-001 through clinical phases
- Additional remuneration disclosed for interim Executive Chair role
Leadership Change at a Critical Juncture
Neurizon Therapeutics Limited, a clinical-stage biotech focused on neurodegenerative diseases, has announced a significant leadership transition with the resignation of its Managing Director and CEO, Dr Michael Thurn. Effective 16 March 2026, Dr Thurn will step down from his executive duties but will remain on the board as a non-executive director through his notice period, concluding in July 2026. This move marks a pivotal moment for the company as it continues to advance its lead drug candidate, NUZ-001, targeting amyotrophic lateral sclerosis (ALS).
Steady Hands During Transition
To ensure stability during this period, Neurizon has appointed Executive Chair Sergio Duchini as interim Executive Chair. Mr Duchini will oversee the company’s clinical and corporate development programs, maintaining momentum on ongoing initiatives. The board has also disclosed an additional monthly remuneration of $30,000 for Mr Duchini’s expanded responsibilities. This interim leadership arrangement reflects the company’s commitment to disciplined execution amid the search for a permanent CEO.
Global Search for New CEO Underway
Neurizon has engaged Coulter Partners, a leading global executive search firm, to assist in recruiting a new CEO. The company emphasises that the search is aligned with its established succession protocols, aiming to find a leader capable of steering Neurizon through its next growth phase. While no timeline has been provided for the appointment, the board has pledged to keep stakeholders informed as developments arise.
Legacy of Progress Under Dr Thurn
Dr Thurn’s tenure has been marked by notable achievements, including the transition from PharmAust to Neurizon Therapeutics, progression of NUZ-001 through Phase 1 clinical trials, and securing entry into the prestigious HEALEY ALS Platform Trial. His leadership also facilitated strategic partnerships, notably with Elanco, strengthening the company’s intellectual property and regulatory positioning. Both Dr Thurn and Mr Duchini expressed gratitude and optimism about the company’s future, underscoring a smooth transition and continued focus on delivering meaningful outcomes for patients and shareholders.
Looking Ahead
As Neurizon navigates this leadership change, the biotech’s experienced management team remains committed to advancing its clinical programs on schedule. The company’s focus on addressing the unmet medical needs in neurodegenerative diseases, particularly ALS, positions it as a noteworthy player in a challenging therapeutic area. Investors and observers will be watching closely to see how the new CEO shapes Neurizon’s strategic direction and clinical progress in the months ahead.
Bottom Line?
Neurizon’s leadership transition sets the stage for a new chapter; one that will test the company’s resilience and strategic clarity.
Questions in the middle?
- Who will be the new CEO and what experience will they bring to Neurizon?
- How might the leadership change impact the timeline and progress of NUZ-001’s clinical trials?
- Will the company’s strategic partnerships and regulatory engagements continue seamlessly during the transition?